The impact of subsequent metastases on costs and medical resource use (MRU) for prostate cancer (PC) patients initially diagnosed with localized disease was estimated. METHODS: Surveillance, Epidemiology, and End Results data, linked to Medicare (1999Medicare ( -2012, were used to identify 7482 patients diagnosed with subsequent metastases 12 months or more after the initial diagnosis of localized PC (cases), and they were matched to 25,709 localized PC patients without subsequent metastases (controls). Patients were followed for costs and MRU from 12 months before their index date (subsequent metastases or a matched date for controls) up to 12 months after it. Costs and MRU were stratified by the setting/type of care/service. Multivariate mixed effects regression analyses were used to construct and compare longitudinal trajectories of marginal predicted costs and predicted probabilities of MRU between cases and controls. RESULTS: Among the controls, predicted monthly costs remained relatively stable throughout the entire observation period (weighted mean per patient per month, $2746; range during 24 months, $2603-2858). In contrast, among the cases, costs increased from $2622 (95% confidence interval [CI], $2525-2719) 12 months before the diagnosis of subsequent metastases to $4767 (95% CI, $4623-4910) 1 month before the diagnosis of subsequent metastases, peaked during the month of metastases at $13,291 (95% CI, $13,148-13,435), and remained significantly higher than costs for the controls thereafter (eg, $4677 at 1 12 months; 95% CI, $4549-4805). Costs and MRU increased across a wide range of settings/types, including inpatient, outpatient, home health, and hospice settings. CONCLUSIONS: In PC patients initially diagnosed with localized disease, a diagnosis of subsequent metastases is associated with substantially increased costs and MRU. Cancer 2017;123:3591-601.
INTRODUCTION
The development of metastases in patients initially diagnosed with localized prostate cancer (PC) is a seminal event of progression and results in excess morbidity, mortality, and cost. Estimates of the long-term incidence of metastases in localized PC vary considerably with the mode of PC diagnosis 1, 2 and with patient-specific risk factors. [3] [4] [5] In a clinical trial conducted before the era of prostate-specific antigen (PSA) testing, 26.1% of those assigned to receive radical prostatectomy for localized disease had developed distant metastases after 18 years of follow-up, 1 whereas 4.7% had after 15 years of follow-up in a clinical trial of patients diagnosed by means of PSA testing. 2 Risk factors identified in observational studies based on registry data include the PSA level, Gleason score, clinical tumor stage, age at diagnosis, and percentage of biopsy cores involved with cancer. 3, 4 Although estimates of the long-term incidence of metastases in localized PC vary considerably, it is well established that the vast majority of metastases-approximately 80%-are to the bone. [6] [7] [8] Moreover, among patients diagnosed with bone metastases, 40% to 50% will experience at least 1 skeletal-related event (SRE), 9 which is defined as a pathologic fracture, spinal cord compression, or the need for radiation or surgery to the bone. Compared with nonmetastatic PC, bone metastases are associated with a 2-to 7-fold increase in the risk of death, [9] [10] [11] and the risk is even higher among patients with bone metastases and at least 1 SRE. plus docetaxel versus ADT alone, for metastatic, hormone-sensitive PC (study E3805), the median time to the development of castration-resistant (biochemical, symptomatic, or radiographic) PC was 11.7 months with ADT alone. 15 Systemic therapy options for metastatic, castration-resistant PC include chemotherapy (docetaxel/ prednisone, mitoxantrone/prednisone, or cabazitaxel), immunotherapy (sipuleucel-T), abiraterone/prednisone, enzalutamide, secondary hormone therapy, and radium-223 for symptomatic bone metastases in the absence of visceral metastases along with palliative radiation therapy for painful bony metastases and best supportive care. 16 Clinicians must navigate enormous challenges when they are making appropriate treatment decisions for individual patients who have progressed to metastatic, castration-resistant PC. 17 Among these, each type of systemic therapy has specific indications, their use is not mutually exclusive, and there is a lack of data from trials comparing the efficacy/effectiveness of alternative sequences of therapies. Clinical decision making is further complicated when individual patient factors are considered, including the performance status, location of lesions, and presence or absence of focal pains as well as the need to incorporate patient preferences for possible tradeoffs between quality of life and life expectancy, to assess patient tolerance for the risk of adverse treatment effects, and to consider the financial burden of drugs and other care on patient out-of-pocket costs. 17 In addition to diminished survival, metastases and their consequences are associated with increased medical resource use (MRU) 9, 18 and costs. 9, [19] [20] [21] [22] [23] [24] The inflationadjusted costs of hospital admissions for bone metastases in PC are estimated to have risen between 1998 and 2010 from $789 million to $1512 million, with the costs of admissions for SREs increasing from $190 million to $369 million during the same period. 20 Other PC-related costs have increased over the past 15 years; they include palliative radiation for bone metastases in the last year of life, the cost of which increased from an average of $2763 in 2000 to $3989 in 2007, in part because of the complexity of the radiation delivered. 19 The introduction of novel antiresorptives such as zoledronic acid and denosumab has piqued interest in measuring the incremental MRU and costs of SREs in PC patients with bone metastases 9, [19] [20] [21] [22] [23] [24] [25] ; estimates are in the range of $20,000 to 30,000 per patient, 9, 22 and costs are as high as $89,000 per event requiring surgery. 25 Although observational studies of the economic burden of SREs are important for estimating the real-world costs and resource benefits of therapeutic agents that could help to prevent or manage this complication, they do not provide a full accounting of the total economic impact of progression to metastatic disease in patients initially diagnosed with localized disease or the range of diagnostic, therapeutic, and supportive care services required to provide comprehensive care for patients who do progress. The objective of this study was to estimate the impact of developing subsequent metastases on costs and MRU for PC patients initially diagnosed with localized disease. Quantifying the total cost and resource impacts of metastatic disease provides a context for, and informs the value of, potential treatments targeting a delay in or the prevention of progression to subsequent metastases.
MATERIALS AND METHODS

Data Source
This study used data from the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registry, which is linked to Medicare enrollment data and insurance claims. This database has been described in detail elsewhere. 26 As of 2016, SEER collects and publishes cancer incidence and survival data from 20 population-based cancer registries 27 throughout the United States covering approximately 30% of the population. At the time this study was performed, the SEERMedicare linkage included all Medicare-eligible persons appearing in SEER data through 2011 and their Medicare claims through 2012. This study was conducted as part of a protocol submitted to the New England Institutional Review Board (NEIRB). On September 9, 2014 NEIRB granted a determination of exemption for this protocol, based on the fact that the information in the data files is recorded in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Study Design
This was a retrospective cohort study in which the cases were patients who developed subsequent metastases after an initial diagnosis of localized PC, and the controls were patients diagnosed with localized PC who did not develop subsequent metastases. The control patients provided a reference group with which the incremental impact of subsequent metastases on costs and MRU could be assessed.
Initially, patients were included in the study (Fig. 1 ) if they were diagnosed with localized PC between January 1, 2000 and December 31, 2011; localized disease was identified in the SEER registry data with the SEER summary staging variable (SUMM2K1) equal to 1 (localized only). 28 Included patients also were required to have had no prior history of cancer (except for nonmelanoma skin cancer) and to have been enrolled in Medicare fee-forOriginal Article service (FFS) care with no health maintenance organization coverage from 12 months before the initial PC diagnosis through the end of the data collection, which was the date of death or the end of the available Medicare claims data (December 31, 2012), whichever was earlier.
The exclusion of patients with health maintenance organization coverage ensured the availability of full claims and a medical history for each patient.
From this initial cohort, we identified patients who were diagnosed with subsequent metastases 12 months after the initial diagnosis of localized disease (cases). Subsequent metastases were identified with the use of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (lung [197.0] , liver [197.7] , brain or spinal cord [198.3] , and bone [198.5] ) in Medicare claims. This approach was based on a sensitive and specific code-based algorithm that had been validated on the basis of clinical data. 29 In accordance with this algorithm, a single ICD-9-CM code was considered to be sufficient for identifying subsequent metastases.
Each patient diagnosed with subsequent metastases was matched to up to 4 controls who also were selected from the initial cohort of PC patients diagnosed with localized disease but had no evidence of subsequent metastases. Controls were matched to cases by the year of diagnosis, Gleason score, and age. They were assigned an index date that matched the number of months from the diagnosis of localized disease to the diagnosis of subsequent metastases for their corresponding case.
Patients and Variables
Patients were described according to their demographic and clinical characteristics. Age was calculated at the time of metastases for cases and at the assigned index date for controls. Medicare claims were used to reconstruct each patient's history of diagnostic procedures and treatments for localized PC around the time of the initial diagnosis, including surgery, radiation therapy, and ADT. Medicare claims also were used to calculate a National Cancer Institute comorbidity index score for each patient 30, 31 and to identify predictors of a poor performance status, 32 including the use of oxygen and related respiratory therapy supplies, the use of a wheelchair and supplies, the use of a home health agency (HHA), and the use of a skilled nursing facility (SNF).
Patients were followed for costs and MRU from 12 months before their index date (reported as month 0 in figures) to 12 months after it, death, or the end of available Medicare claims (December 31, 2012), whichever came first (Fig. 2 ).
Medical Costs
We calculated the total cost per patient per month from 12 months before the index date to up to 12 months after it while using all of the following types/settings of care/ services: hospital inpatient visits, hospital outpatient/ emergency room visits, physician services, HHA, hospice, SNF, and durable medical equipment (DME). In addition, we calculated the costs of each type/setting of care by combining HHA, hospice, SNF, and DME into 1 category ("other"). Also, we calculated the monthly perpatient costs for managing suspected or confirmed SREs, including all facility and physician claims for pathologic fractures, radiation therapy to the bone, bone surgery, and spinal compression 21 and, separately, the costs of chemotherapy. 24 Oral drugs were not included in the cost calculations because Medicare Part D claim files were not available for the entire observation period of the study. Medicare costs included payments made to the provider and/or beneficiary for the covered service, the Part B deductible for which the beneficiary was liable, payments made on behalf of a Medicare FFS beneficiary by a primary payer other than Medicare, and the beneficiary coinsurance amount. All Medicare costs were inflated to 2012 dollars with the use of the medical care component of the Consumer Price Index. 33 
MRU
MRU was classified in the same way as costs (described previously). For each patient and each type of MRU, we constructed a binary variable for each month in the patient's observation period to indicate whether or not that patient had a record of having received that type of care in that month.
Statistical Analyses
Because the sample sizes were large, rather than testing for the statistical significance of differences between cases and controls, we calculated standardized differences 34 and used them to assess the degree of overlap in the distributions of patient characteristics between the 2 groups. We plotted the mean unadjusted costs (with the 95% confidence intervals [CIs]) and median unadjusted costs (with the interquartile ranges) per month from 12 months before the index date up to 12 months after it (both the overall cost [total cost] and the costs stratified by the setting/type of care). We performed longitudinal mixed effects regression analyses to estimate the mean marginal predicted cost per month (along with the 95% CI), and we made adjustments for baseline demographic and clinical characteristics. Also, we plotted unadjusted probabilities of MRU by the setting/type of care, and we used longitudinal mixed effects logistic regression to estimate the marginal predicted probabilities of MRU per month (along with the 95% CI), with adjustments made for baseline demographic and clinical characteristics. Original Article Finally, we calculated the rates of MRU during the 12 months before the diagnosis of metastases, and we compared them with rates around the diagnosis of subsequent metastases (from -1 month to 1 1 month) to identify the main MRU drivers of costs between the cases.
RESULTS
Overall, 12,401 of the 173,462 patients diagnosed with localized PC (7.1%) between 2000 and 2011 developed subsequent metastases; 7482 of these patients (60.3%) met all the inclusion criteria (Fig. 1) . Therefore, the final cohort included 7482 cases who developed subsequent metastases Table 1 . In general, standardized differences between the cases and the controls were small, and this indicated a high degree of overlap (no differences) in the distributions of the baseline characteristics.
Medical Costs
Longitudinal trajectories of unadjusted and predicted (adjusted) total costs are presented in Figure 3 . Among controls, predicted total costs (Fig. 3B ) remained relatively constant during the entire observation period (weighted mean per patient per month, $2746; range over 24 months, $2603-2858). In contrast, among the cases, costs increased from $2622 (95% CI, $2525-2719) 12 months before the diagnosis of subsequent metastasis to $4767 (95% CI, $4623-4910) 1 month before the diagnosis of subsequent metastasis, peaked during the month of metastasis at $13,291 (95% CI, $13,148-13,435), and remained statistically significantly higher than the costs for controls thereafter (eg, $4677 at 12 months; 95% CI, $4549-4805). A sensitivity analysis, which entailed extending the observation period to 24 months after the index date, showed that large cost differences between cases and controls remained 2 years after metastases (see online supporting information). Inpatient facility costs accounted for almost 50% of the total costs during the month of subsequent metastases (mean, $6244; 95% CI, $6140-6347; Fig. 4A ). However, costs for hospital outpatient/emergency department visits as well as those for hospice, HHA, SNF, and DME (combined as "other") and physician services also increased substantially around the diagnosis of subsequent metastasis, and they remained significantly higher thereafter (Fig.  4B-D) . Among cases, total costs were similar for those who were receiving ADT at the time of diagnosis and those who were not (Fig. 5) before and around the diagnosis of subsequent metastases. However, after diagnosis, costs remained higher for those who were receiving ADT at the time of diagnosis.
MRU
Patterns of MRU followed patterns of costs. Among controls, the proportion of patients who had inpatient admissions or hospital outpatient/emergency room visits, were receiving physician services (for inpatient or outpatient visits), and were receiving other services, including HHA, SNF, and hospice, remained relatively constant or rose slightly during the observation period (Fig. 6 ) from 4.0% (95% CI, 3.7%-4.4%) 12 months before their index date to 5.3% (95% CI, 4.9%-5.8%) 12 months after their index date. In contrast, among cases, although inpatient admission rates were low in the months before the diagnosis of subsequent metastases (3.5% 12 months before metastases; 95% CI, 3.2%-3.9%), 48.6% of cases (95% CI, 46.4%-50.9%) were hospitalized during the month of diagnosis, and the rates for cases remained more than 2-fold higher than those for controls for the remainder of the observation period (12.3% 12 months after metastases; 95% CI, 11.2%-13.6%). Among cases, the largest sustained increase in MRU after diagnosis was for other services, which included HHA, SNF, and hospice (Fig. 6) . Here, the proportion of patients increased from 18.6% (95% CI, 16.7%-20.7%) in the month before the diagnosis of subsequent metastases to 54.2% (95% CI, 50.8%-57.6%) during the month of metastases, and it remained substantially higher thereafter (46.2% 12 months after metastases; 95% CI, 42.8%-49.6%).
A detailed analysis of specific procedures, including those performed within the hospital inpatient and hospital outpatient/emergency room settings (Table 2) , shows substantial increases in the absolute and relative rates of a broad range of procedures around the time of subsequent metastases, including radiation therapy, surgery, laboratory, and general medical services, with rates increasing up to 19-fold from 12 months before the diagnosis of subsequent metastases to the period around the diagnosis (-1 month to 1 1 month). Similar patterns were observed for chemotherapy and treatment for SREs when procedures/ services were combined across all settings/types of care (see online supporting information).
DISCUSSION
Using SEER cancer registry data linked to Medicare insurance claims, we conducted an observational cohort study to estimate the cost and MRU impacts of subsequent Figure 5 . Longitudinal trajectories of total costs stratified by ADT use at the time of subsequent metastases. Longitudinal trajectories of adjusted (predicted) costs are shown for patients initially diagnosed with localized prostate cancer who had subsequent metastases (metastases) and patients who did not have subsequent metastases (no metastases) from 12 months before the date of subsequent metastases or a matched date for controls (index date 5 0) up to 12 months after their index date. Patients diagnosed with subsequent metastases were stratified according to whether or not they were receiving ADT at the time of subsequent metastases. ADT indicates androgen-deprivation therapy; CI, confidence interval. Predicted probability of other services (ie, hospice, home health, skilled nursing facility, and durable medical equipment). In panels A and C the 95% CIs are not shown because they are indistinguishable from point estimates.
metastases for patients initially diagnosed with localized PC. Although previous studies limited the sample selection to PC patients with an incident diagnosis of stage IV disease, 18 included only patients with bone metastases, 9, [19] [20] [21] [22] [23] [24] [25] and/or focused only on the costs of SREs, 19, [23] [24] [25] we identified patients with any type of metastasis, and we followed them for total costs, costs by setting/type of service, and MRU throughout the continuum of diagnosis, treatment, and ongoing supportive care.
Our findings show that medical costs began to rise steadily before metastases were first identified in the claims data, peaked during the month in which metastases were identified, and thereafter remained substantially higher than those for a control group of localized PC patients who did not develop subsequent metastases. Patterns of MRU closely matched those of costs, with rates of radiology, surgery, laboratory, and chemotherapy services increasing up to 19-fold around the time of metastases. Although inpatient facility costs constituted the largest component of total medical costs, substantially higher costs were observed across multiple settings/types of care, and this indicates that progression to subsequent metastases has widespread implications across many types of providers and shows that the clinical complexities of managing these patients translate directly into high costs of care.
The findings have implications as we transition from FFS care to value-based care as legislated by the Medicare Access and CHIP Reauthorization Act of 2015, 35 which introduced the alternative payment model as well as the Merit-Based Incentive Payment System (MIPS). The legislation is meant to incentivize providers to give better quality care to the right patient at the right time. The MIPS, for example, ties provider payments to quality, MRU, clinical practice improvement, and meaningful use of certified technologies. Accountable care organizations, an alternative payment model, are incentivized to manage population costs and to share in risk and potential savings from targeted interventions for their managed population. The analysis of resource use patterns and costs associated with care for PC patients with metastases helps providers to better understand the drivers of increased costs around the time of metastasis and quantifies the extent of those costs; this could help to inform decision making and negotiations by providers under the emerging value-based payment models. The strengths of our study include the fact that we used geographically diverse SEER data to identify PC patients initially diagnosed with localized disease, we used a validated algorithm to identify subsequent metastases in Medicare claims, 29 we were able to capture most MRU in claims, and we used an analytic approach designed to measure within-person changes in resource use and costs over time and differences between patients with and without subsequent metastases. One limitation of combining SEER and Medicare is that it requires restricting the cohort to patients who are 65 years old or older. Therefore, our findings might not be generalizable to younger patients. To the extent that younger patients receive more intensive therapy for metastases, we might expect to see larger cost differences in a cohort that included younger patients. The algorithm that we used to identify metastases 29 was based on data from 1 institution, and although it was accurate, it is possible that patients in the metastasis and control groups were misclassified; this may have resulted in our underestimating the true survival, MRU, and cost differences between the 2 groups. Furthermore, because our study included patients diagnosed with locoregional disease in 2000, we could not include claims for oral drugs in our analyses. Although most characteristics were reasonably balanced between cases and controls, there were differences in comorbidity, treatment of localized disease, and indicators of poor performance. Therefore, we conducted multivariate analyses of costs and MRU to account for these differences. Finally, although our study does help to quantify the cost of developing metastatic PC, it was not designed to allow us to comment on the impact of definitively treating localized disease on preventing costs related to metastasis.
In conclusion, our findings demonstrate that the enormous challenges clinicians currently must navigate in making appropriate treatment decisions for individual patients who have progressed to metastatic PC equate to high costs and excess resource use across a broad spectrum of health-care providers and services. As the United States continues to transition physician reimbursement from FFS to reimbursement based on performance categories that include resource use (eg, MIPS), it seems inevitable that clinicians will bear an increased share of responsibility for controlling MRU and costs while at the same time being accountable for improving quality and outcomes across a broad spectrum of clinical and patient-reported metrics. Because of the current clinical challenges attendant to managing metastatic PC, novel strategies will be required. Validated clinical pathways within electronic health care records, coordinated care strategies of enhanced communication with both physician and nonphysician stakeholders, and improvements in patient education and therapeutic compliance all are likely to play important roles. Our findings may provide a benchmark from which targets can be set for improving the efficiency of care and from which the economic impact of specific strategies can be assessed.
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